FDA Approves GLP-1 Drugs for Fatty Liver Disease With 63% Success Rate
The FDA recently approved GLP-1 medications like semaglutide (Ozempic/Wegovy) for treating non-alcoholic fatty liver disease, which affects 38% of Americans. Major clinical trials show these drugs can reverse fatty liver disease in 44-63% of patients without worsening liver scarring. A 2024 study found tirzepatide achieved 62% resolution rates at the highest dose, while semaglutide resolved the condition in 62.9% of over 1,100 patients. However, these medications must be combined with adequate protein intake (1.2g per kg body weight), resistance exercise, and lifestyle changes to preserve muscle mass during weight loss. Additional recommendations include avoiding alcohol, managing heart disease risk factors, drinking black coffee, and maintaining adequate vitamin D levels.